how many glp-1 agonists are there Market Exclusive Research Report 2025 Science Behind GLP 1 GIP

Description

Protein kinases: mechanisms and downstream targets in inflammation-mediated obesity and insulin resistance

doi: 10.7150/thno.67167 Summary Keywords polycystic ovary syndrome, gut microbiota, metabolic disorders, insulin resistance, bile acids Citation Li J, Qiao J, Li Y, Qin G, Xu Y, Lao K, Wang Y, Fan Y, Tang P and Han L (2025) Metabolic disorders in polycystic ovary syndrome: from gut microbiota biodiversity to clinical intervention

Breast adenocarcinoma Prostate adenocarcinoma Non-small cell lung cancer (NSCLC) Colorectal adenocarcinoma Hepatocellular carcinoma (liver cancer) Renal cell carcinoma Pancreatic adenocarcinoma Half of the participants started a GLP-1 medication semaglutide, tirzepatide, dulaglutide, liraglutide, lixisenatide or pramlintide after their cancer diagnosis